Tofacitinib in Patients With Amyotrophic Lateral Sclerosis
Tofacitinib in Patients With Amyotrophic Lateral Sclerosis
Not yet recruiting · NCT06689982 · Registry updated 2024-11-15Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Tofacitinib in Patients With Amyotrophic Lateral Sclerosis | Inflammation, Neuroinflammatory Diseases, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, TDP-43 proteinopathy, amyotrophic lateral sclerosis, central nervous system disorder, metabolic disease, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, proteostasis deficiencies, spinal cord disorder | Not yet recruiting | Early phase 1 | 2024-11-15 | NCT06689982 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Beijing Tiantan Hospital | 307 |
| Turing-Darwin Laboratory; West Institute of Computing Technology, Chongqing, China | 1 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Beijing Tiantan Hospital | Beijing | China | 5 |